Skip to main content
Clinical Trials/JPRN-UMIN000024330
JPRN-UMIN000024330
Unknown
Phase 2

A phase II study of combination chemotherapy of oral tegafur/uracil, leucovorin and bevacizumab for patients not appropriate for intensive therapy with unresectable or recurrent colorectal cancer - A phase II study of UFT/LV and bevacizumab treatment

Dept of Surgical Oncology Osaka City University Graduate School of Medicine0 sites35 target enrollmentOctober 7, 2016

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
unresectable metastatic/recurrent colorectal cancer
Sponsor
Dept of Surgical Oncology Osaka City University Graduate School of Medicine
Enrollment
35
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 7, 2016
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dept of Surgical Oncology Osaka City University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Patients with a past history of severe drug allergy 2\)no other co\-existing malignancy or malignancy within the last five years prior to enrollment other than non\-melanoma skin cancer or in situ carcinoma of the cervix 3\)patients were pregnant or lactating 4\)Patients with psychiatric illness 5\)Patients with severe co\-morbidities (renal failure, liver dysfunction, uncontrolable diabetes mellitus and hypertension, heart failure) 6\)Patients with massive ascites or hydrothorax 7\)Patients with a symptomatic brain metastasis 8\)Patients with abdominal surgery within 28days 9\)Patients with perforated disease 10\)Patients with thrombosis 11\)Patiens with 3\+ proteinurea

Outcomes

Primary Outcomes

Not specified

Similar Trials